Probity Advisors Inc. Has $616,000 Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Probity Advisors Inc. grew its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 9.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 43,296 shares of the company’s stock after purchasing an additional 3,661 shares during the period. Probity Advisors Inc.’s holdings in Takeda Pharmaceutical were worth $616,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Creative Planning grew its position in shares of Takeda Pharmaceutical by 46.3% during the 3rd quarter. Creative Planning now owns 157,630 shares of the company’s stock worth $2,242,000 after purchasing an additional 49,871 shares in the last quarter. Exchange Traded Concepts LLC grew its position in shares of Takeda Pharmaceutical by 77.7% during the 3rd quarter. Exchange Traded Concepts LLC now owns 63,471 shares of the company’s stock worth $903,000 after purchasing an additional 27,756 shares in the last quarter. Ritholtz Wealth Management grew its position in shares of Takeda Pharmaceutical by 11.7% during the 3rd quarter. Ritholtz Wealth Management now owns 27,169 shares of the company’s stock worth $386,000 after purchasing an additional 2,850 shares in the last quarter. First Affirmative Financial Network bought a new stake in shares of Takeda Pharmaceutical during the 3rd quarter worth approximately $226,000. Finally, Hexagon Capital Partners LLC lifted its holdings in shares of Takeda Pharmaceutical by 34.3% during the 3rd quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock worth $63,000 after acquiring an additional 1,129 shares during the period. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Shares of Takeda Pharmaceutical stock opened at $14.08 on Thursday. The company has a 50 day moving average of $14.59 and a 200-day moving average of $13.75. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.08. The company has a current ratio of 1.26, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. The company has a market cap of $44.80 billion, a PE ratio of 26.57, a price-to-earnings-growth ratio of 0.27 and a beta of 0.54.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. The company had revenue of $7.75 billion during the quarter. As a group, equities research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.58 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.